Reps Prep Sunscreen Filter Legislation; FDA Frustrated By Backlog
This article was originally published in The Rose Sheet
Executive Summary
Without swift FDA action on eight sunscreen filters pending review, legislators intend to introduce a bill to alter the agency’s sunscreen approval process. House members questioned FDA Center for Drug Evaluation and Research Director Janet Woodcock on the status of the applications, some of which have been under agency review for more than 10 years.
You may also be interested in...
Sunscreen Ingredient Legislation Could Ride Wave Of Momentum
Legislators and stakeholders are optimistic that the Sunscreen Innovation Act, which calls for an acceleration of FDA’s review of sunscreen active-ingredient time-and-extent applications, will pass this year. The House version of the bill is expected to advance first.
Sunscreen Bill Would Expedite TEA Decisions, Set Deadlines
The Sunscreen Innovation Act, introduced in both the House and the Senate, would streamline the process for FDA review of sunscreen TEAs and impose deadlines for agency action.
FDA Rejects Sunscreen TEAs, Plans Public Hearing On Ingredient Review
FDA announces that it has found data insufficient to affirm the safety of two of the eight pending time-and-extent applications for sunscreen actives – amiloxate and diethylhexyl butamido triazone, marketed under the trade names NeoHeliopan and Uvasorb HEB. The agency invites the public and manufacturers, to submit further information in support of the actives’ safety.